HP802-247 fails Phase III trial for treatment of Venous Leg Ulcers-Smith & Nephew

Smith & Nephew the global medical technology business, announced top-line results from a Phase III study of HP802-247, a living cell spray-on therapy designed to work with the body's own cells to stimulate healing of venous leg ulcers ("VLUs"). HP802-247 did not meet the primary endpoint, namely a statistically significant improvement in healing over placebo, in a randomized, double-blind, vehicle-controlled study in North America. A full analysis of the efficacy data and study methodology is underway and will be completed in the coming months. A second Phase III study in the European Union, which is expected to report in 2016, will continue while the programme analysis is completed.